Analysts expect HCA Healthcare Inc (NYSE:HCA) to announce sales of $12.62 billion for the current fiscal quarter, Zacks Investment Research reports. Eleven analysts have provided estimates for HCA Healthcare’s earnings, with the highest sales estimate coming in at $12.72 billion and the lowest estimate coming in at $12.57 billion. HCA Healthcare posted sales of $11.53 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 9.5%. The company is expected to announce its next earnings results on Wednesday, July 24th.
According to Zacks, analysts expect that HCA Healthcare will report full year sales of $50.98 billion for the current fiscal year, with estimates ranging from $50.72 billion to $51.16 billion. For the next fiscal year, analysts expect that the company will post sales of $53.44 billion, with estimates ranging from $52.61 billion to $54.18 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover HCA Healthcare.
HCA Healthcare (NYSE:HCA) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $2.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.31 by $0.66. The company had revenue of $12.52 billion for the quarter, compared to analysts’ expectations of $12.34 billion. HCA Healthcare had a net margin of 7.71% and a negative return on equity of 112.65%. HCA Healthcare’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.18 EPS.
A number of brokerages recently issued reports on HCA. Zacks Investment Research upgraded shares of HCA Healthcare from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a research note on Friday, May 3rd. UBS Group upped their target price on shares of HCA Healthcare from $164.00 to $172.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Deutsche Bank upped their target price on shares of HCA Healthcare from $160.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Raymond James upgraded shares of HCA Healthcare from a “market perform” rating to an “outperform” rating and upped their target price for the company from $115.00 to $135.00 in a research note on Tuesday, April 23rd. Finally, Jefferies Financial Group set a $158.00 target price on shares of HCA Healthcare and gave the company a “buy” rating in a research note on Wednesday, April 17th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $149.41.
HCA Healthcare stock traded up $0.06 during mid-day trading on Wednesday, reaching $128.21. The stock had a trading volume of 1,012,800 shares, compared to its average volume of 1,801,879. The stock has a market cap of $43.75 billion, a price-to-earnings ratio of 13.12, a PEG ratio of 0.99 and a beta of 0.75. HCA Healthcare has a one year low of $101.30 and a one year high of $147.42.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 3rd will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 1.25%. The ex-dividend date of this dividend is Friday, May 31st. HCA Healthcare’s payout ratio is currently 16.38%.
In other news, insider Jon M. Foster sold 44,281 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $122.28, for a total transaction of $5,414,680.68. Following the completion of the sale, the insider now owns 96,052 shares of the company’s stock, valued at approximately $11,745,238.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HCA. Benjamin F. Edwards & Company Inc. acquired a new position in HCA Healthcare during the 4th quarter worth about $25,000. Sontag Advisory LLC bought a new stake in HCA Healthcare in the fourth quarter valued at about $26,000. Doyle Wealth Management bought a new position in shares of HCA Healthcare during the fourth quarter valued at approximately $31,000. Kore Private Wealth LLC bought a new position in shares of HCA Healthcare during the first quarter valued at approximately $33,000. Finally, Trust Co. of Vermont grew its holdings in shares of HCA Healthcare by 165.3% during the fourth quarter. Trust Co. of Vermont now owns 329 shares of the company’s stock valued at $41,000 after purchasing an additional 205 shares during the last quarter. 71.66% of the stock is owned by hedge funds and other institutional investors.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Featured Article: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.